参考文献
|
-
Basch, E,Prestrud, AA,Hesketh, PJ(2011).Antiemetic American Society of Clinical Oncology clinical practice guideline update.J Clin Oncol,29,4189-4198.
-
Boccia, RV,Gordan, LN,Clark, G(2011).Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, doubleblind, phase III study.Support Care Cancer,19,1609-1617.
-
Chiu, L,Chiu, N,Chow, R(2016).Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.Ann Palliat Med,5,172-178.
-
de Wit, R,de Boer, AC,vd Linden, GHM(2001).Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy.Br J Cancer,85,1099-1101.
-
Inoue, T,Kimura, M,Uchida, J(2017).Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.Int J Clin Oncol,22,600-604.
-
Lau, TKH,Yip, CHW,Yeo, W(2016).State of the art antiemetic therapy for cancer patients.Curr Oncol Rep,18,2.
-
Navari, RM,Nagy, CK,Gray, SE(2013).The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.Support Care Cancer,21,1655-1663.
-
Roila, F,Herrstedt, J,Aapro, M(2010).Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.Ann Oncol,21,232-243.
-
Tamura, K,Aiba, K,Saeki, T(2017).Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.Int J Clin Oncol,22,405-412.
-
Yang, LQ,Sun, XC,Qin, SK(2016).Transdermal granisetron for the prevention of nausea and vomiting following moderatelyor highly emetogenic chemotherapy in Chinese patients: a randomized, doubleblind, phase III study.Chin Clin Oncol,5,79e1-79e8.
|